St. David’s South Austin evaluating new antiviral for coronavirus -Statesman

The hospital was asked to register 10-15 clients into the randomized trial by ViralClear Pharmaceuticals Inc. and has already done so, said Dr. Matthew Robinson, medical director of infectious disease at St. David’s South Austin, however will continue enrolling clients up until it is informed the study is no longer accepting individuals.

St. David’s South Austin already has actually been dealing with patients with another antiviral, remdesivir, as well as a steroid, dexamethasone, and convalescent plasma from individuals who have had the infection and recovered.

Antivirals are most reliable when given in the disease’s early phases, which has been a difficulty with this stud